Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.42 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | SNCA | P37840 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | RHOA | P61586 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2070390 | 0.89 | MAPT (0.39) | MAPTCACNA1BAPBA1CYP3A4ALDH1A1 | |
| SCHEMBL12006510 | 0.84 | — | — | |
| SCHEMBL6212156 | 0.84 | TSHR (0.49) | MAPTCYP3A4ALDH1A1TSHRHSD17B10 | |
| SCHEMBL5134780 | 0.80 | MAPT (0.39) | MAPTCACNA1BAPBA1CYP3A4ALDH1A1 | |
| SCHEMBL3673218 | 0.78 | — | — | |
| SCHEMBL797852 | 0.76 | — | — | |
| SCHEMBL461759 | 0.76 | — | — | |
| SCHEMBL18756267 | 0.76 | MAPT (0.36) | MAPTCACNA1BAPBA1CYP3A4ALDH1A1 | |
| SCHEMBL1906085 | 0.74 | TSHR (0.41) | MAPTCACNA1BAPBA1CYP3A4ALDH1A1 | |
| SCHEMBL9482612 | 0.74 | CYP3A4 (0.39) | MAPTCACNA1BAPBA1CYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902381-B2 | Synthesising method and benzoxathiepine intermediates | PIERRE FABRE MEDICAMENT (FR) | 2011-03-08 | — | — | US | disclosed |
| US-20080234499-A1 | Synthesising Method and Benzoxathiepine Intermediates | PIERRE FABRE MEDICAMENT (FR) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234499-A1 | Synthesising Method and Benzoxathiepine Intermediates | CYP2F1, CYP2E1, CBR1 | MAPT 4418/4885CACNA1B 2673/4885APBA1 2180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.